POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular tonicity, nerve conduction, muscle contraction, and renal function. Dextrose provides calories and is metabolized as a source of energy. Sodium chloride provides sodium and chloride ions, which are major extracellular cations and anions, respectively, contributing to fluid and electrolyte balance.
| Metabolism | Potassium is not metabolized; it is primarily excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis and the citric acid cycle. Sodium and chloride are not metabolized; sodium is excreted mainly by the kidneys. |
| Excretion | Renal: potassium is primarily excreted by the kidneys (90%) with a small amount lost in feces (10%); dextrose and sodium are essentially completely reabsorbed or metabolized. |
| Half-life | The terminal elimination half-life of potassium is 2-3 hours in healthy individuals, but may be prolonged in renal impairment or with high potassium loads. |
| Protein binding | Potassium: essentially unbound (<1%); dextrose and sodium are not protein bound. |
| Volume of Distribution | Potassium: 0.35 L/kg (total body water); dextrose distributes into total body water; sodium distributes into extracellular fluid (0.2 L/kg). |
| Bioavailability | Intravenous: 100% bioavailability; not administered via other routes for systemic effect. |
| Onset of Action | Intravenous: rapid onset of action within minutes to correct hypokalemia; dextrose distribution occurs within minutes, but metabolic effects on glucose may take 15-30 minutes. |
| Duration of Action | Intravenous: effect lasts 2-4 hours depending on infusion rate and patient's potassium balance; dextrose effect sustained during infusion. |
| Molecular Weight | 74.55 |
Adult: Intravenous infusion. Rate and volume depend on clinical status. Typical maintenance: 100-200 mL/h. Maximum infusion rate: 0.5-1 mEq/kg/h (potassium).
| Dosage form | INJECTABLE |
| Renal impairment | GFR > 50 mL/min: no adjustment. GFR 10-50 mL/min: reduce by 50% or extend interval. GFR < 10 mL/min: avoid or use with extreme caution, reduce dose by 75%. |
| Liver impairment | No specific adjustment required for Child-Pugh A or B. Child-Pugh C: use with caution, monitor electrolytes closely. |
| Pediatric use | Children: IV infusion based on weight. Typical maintenance: 100 mL/kg/day for first 10 kg, 50 mL/kg/day for next 10 kg, 20 mL/kg/day for each kg >20 kg. Potassium content adjusted to 0.15% (2 mEq/100 mL) but rate limited to 0.5-1 mEq/kg/h. |
| Geriatric use | Elderly: Use lower end of dosing range due to decreased renal function. Monitor serum potassium and renal function closely. Avoid rapid infusion. |
| 1st trimester | Potassium chloride in low concentrations (0.15%) is considered safe for use during first trimester when administered at recommended doses for fluid and electrolyte maintenance. However, caution is advised as potassium imbalances can affect maternal and fetal well-being. |
| 2nd trimester | Safe for use during second trimester for replacement therapy in hypokalemia or maintenance of electrolyte balance. Monitor serum potassium levels closely to avoid hyperkalemia, which can cause adverse fetal effects. |
| 3rd trimester | Safe during third trimester when used for fluid and electrolyte maintenance. Potassium supplementation should be guided by serum levels to prevent hyperkalemia, which may lead to fetal arrhythmias or other complications. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium crosses the placenta via active transport and passive diffusion. Fetal serum potassium levels are slightly higher than maternal levels. Administration of potassium chloride at therapeutic doses does not result in excessive fetal exposure. |
| Breastfeeding | Potassium chloride is a normal constituent of breast milk. Administration of potassium chloride intravenously at standard replacement doses does not significantly alter milk potassium levels or pose risk to the nursing infant. However, caution is advised in cases of maternal hyperkalemia or renal impairment. |
| Lactation Rating | Safe |
| Teratogenic Risk | Potassium chloride and dextrose at these concentrations are not associated with teratogenicity. Sodium chloride is physiological. However, maternal electrolyte imbalances (hyperkalemia, hypernatremia) may affect fetal homeostasis. No specific trimester risks are documented at standard therapeutic doses. |
| Fetal Monitoring | Monitor maternal serum electrolytes (potassium, sodium, glucose), fluid balance, and renal function. Fetal monitoring (heart rate, growth) if maternal metabolic disturbances occur. |
| Fertility Effects | No known adverse effects on fertility from potassium chloride, dextrose, or sodium chloride at therapeutic doses. |
■ FDA Black Box Warning
Do not infuse undiluted potassium chloride. High plasma concentrations of potassium may cause hyperkalemia, cardiac arrest, or fatal arrhythmias. Use with caution in patients with renal impairment or conditions predisposing to hyperkalemia.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaHyperkalemic periodic paralysisConcurrent use of potassium-sparing diuretics (e.g., spironolactone, eplerenone) without close monitoringAddison's disease (untreated)Severe hemolytic reactions or crush injuries (risk of hyperkalemia)
| Precautions | Risk of hyperkalemia, especially in patients with renal impairment, adrenal insufficiency, or massive tissue trauma, Electrocardiographic monitoring recommended if high potassium concentrations are infused, Risk of fluid overload or electrolyte disturbances, Use with caution in patients with heart failure, edema, or conditions requiring sodium restriction, Assess renal function before administration |
| Food/Dietary | Avoid excessive potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, tomatoes, avocados) while receiving this infusion to reduce risk of hyperkalemia. Dextrose content may affect blood glucose; patients with diabetes should monitor glucose levels. |
| Clinical Pearls | Monitor serum potassium, glucose, and sodium levels frequently. Avoid rapid infusion to prevent hyperkalemia or fluid overload. Use with caution in renal impairment, heart failure, or conditions predisposing to hyperkalemia. Do not administer if solution is cloudy or contains precipitate. Incompatible with amphotericin B and mannitol. |
| Patient Advice | This infusion provides potassium, dextrose (sugar), and sodium to correct electrolyte and fluid imbalances. · Notify your healthcare provider immediately if you experience chest pain, difficulty breathing, muscle weakness, or irregular heartbeat. · Do not stop the infusion or adjust the rate yourself. · Inform your doctor about all medications, especially potassium supplements, diuretics, or ACE inhibitors. · Report any signs of infection at the IV site, such as redness, swelling, or pain. |
Loading safety data…